0001493152-26-021108
SEC filingOperating loss narrowed on cost discipline, but net income fell sharply as trust interest income declined, while the pending business combination faces CSRC approval delays.
For the fiscal year ended December 31, 2025, Aimei Health Technology Co., Ltd reported an operating loss of -$836K, improving 21.5% from -$1.1M in FY2024. This improvement was driven by a reduction in general, administrative and operational costs, which fell to $836K from $1.1M. As a blank check company with no operating revenue, these expenses primarily reflect costs related to being a public company (legal, financial reporting, accounting, auditing) and due diligence activities for the proposed business combination. The narrowing loss signals management's focus on cost containment while pursuing the transaction.
Net income for FY2025 was $1.1M, down 58.5% from $2.6M in FY2024. The decline is attributable to lower interest income earned on the trust account, which decreased as the trust balance was reduced following redemptions and expenses. The company generates non-operating income from interest on cash and investments held in the trust account, which is expected to continue but at lower levels given the reduced trust balance.
The proposed business combination with United Hydrogen has been approved by shareholders but awaits a filing notice from the China Securities Regulatory Commission (CSRC). The company has no assurance that the transaction will be consummated by the applicable deadline. If not, the company will be forced to liquidate, redeeming public shares from the trust account and ceasing operations.
Management's outlook emphasizes that the company will not generate operating revenue until a business combination closes. Non-operating income from trust interest will continue but at lower levels given the reduced trust balance. The primary risk is the timing and outcome of CSRC approval for the United Hydrogen transaction. If the business combination is not consummated by the deadline, the company will be forced to liquidate, redeeming public shares from the trust account and ceasing operations. The rights included in the units would expire worthless. The company's limited cash outside the trust and working capital deficit underscore the urgency of completing a transaction.